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A B S T R A C T   
Depression is frequently associated with sleep problems, and clinical improvement often coincides with the 
normalization of sleep architecture and realignment of circadian rhythm. The effectiveness of treatments tar-
geting sleep in depressed patients, such as sleep deprivation, further demonstrates the confluence of sleep and 
mood. Moreover, recent studies showing that the rapid-acting antidepressant ketamine influences processes 
related to sleep-wake neurobiology have led to novel hypotheses explaining rapid and sustained antidepressant 
effects. Despite the available evidence, studies addressing ketamine’s antidepressant effects have focused on 
pharmacology and often overlooked the role of physiology. To explore this discrepancy in research on rapid- 
acting antidepressants, we examined articles published between 2009–2019. A keyword search algorithm 
indicated that vast majority of the articles completely ignored sleep. Out of the 100 most frequently cited pre-
clinical and clinical research papers, 89 % and 71 %, respectively, did not mention sleep at all. Furthermore, only 
a handful of these articles disclosed key experimental variables, such as the times of treatment administration or 
behavioral testing, let alone considered the potential association between these variables and experimental 
observations. Notably, in preclinical studies, treatments were preferentially administered during the inactive 
period, which is the polar opposite of clinical practice and research. We discuss the potential impact of this 
practice on the results in the field. Our hope is that this perspective will serve as a wake-up call to (re)-examine 
rapid-acting antidepressant effects with more appreciation for the role of sleep and chronobiology.   
1. Introduction 
The discovery of ketamine’s rapid antidepressant effects is arguably 
one of the most substantial advances in modern psychiatry. In contrast 
to conventional antidepressant drugs, which may require up to months 
of daily use before depressive symptoms are attenuated, a single infusion 
of subanesthetic-dose ketamine often relieves symptoms in mere hours 
(Berman et al., 2000; Diazgranados et al., 2010; Fava et al., 2020; 
Murrough et al., 2013; Zarate et al., 2012, 2006). Depressive symptoms 
are alleviated gradually, often reported to peak on the day following the 
treatment (aan het Rot et al., 2012; Berman et al., 2000; Coyle and Laws, 
2015). However, ketamine’s antidepressant effects typically last for only 
up to a week, and some individuals do not achieve remission despite 
repeated administration (Phillips et al., 2019). These limitations have 
prompted unprecedented scientific inquiry into extending and rein-
forcing ketamine’s therapeutic effects or identifying an alternative, 
equally effective antidepressant agent that has fewer psychotomimetic 
effects. 
Pharmacological, molecular, and functional effects associated with 
ketamine’s antidepressant effects have been extensively studied 
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(Rantamäki and Kohtala, 2020; Zanos et al., 2018a). An emerging 
consensus highlights a central role of the stimulation of excitatory glu-
tamatergic neurotransmission occurring primarily—although not 
exclusively—in the medial prefrontal cortex (Covington et al., 2010; 
Duman et al., 2016; Fogaça et al., 2020; Fuchikami et al., 2015; Hare 
et al., 2019; Kadriu et al., 2019; Kohtala et al., 2019; Kraus et al., 2019; 
Krystal et al., 2019, 2013; Rantamäki and Kohtala, 2020). Animal 
studies have identified numerous receptor-level changes and molecular 
pathways, many converging on mechanisms of synaptic plasticity and 
synaptogenesis, necessary for the rapid and sustained antidepressant 
effects of ketamine (Autry et al., 2011; Li et al., 2010b; Moda-Sava et al., 
2019). However, the past two decades of drug discovery research have 
not been able to produce a single compound matching ketamine’s 
therapeutic efficacy; on the contrary, several promising drug candidates 
have failed in clinical trials (Garay et al., 2018; Kadriu et al., 2019). 
The lack of translational success in the antidepressant field has 
traditionally been explained by poor construct validity of animal models 
of depression that are unable to capture the exclusively human aspects 
of the disorder (Cryan and Holmes, 2005; Harmer et al., 2010; Hasler 
et al., 2004; Nestler et al., 2002). However, it has become increasingly 
evident that many other physiological variables, such as selection of 
animal species and strain, biological sex and age of the animals, and 
even gut microbiota have a major impact on study outcomes and should 
be properly addressed in experimental design (Cryan and Holmes, 2005; 
Franklin and Ericsson, 2017; Võikar et al., 2001). Surprisingly, the effect 
of sleep—the most prominent neurophysiological change that occurs 
between ketamine treatment and the emergence of maximum treatment 
responses—has not received much attention. This work presents a 
perspective of why sleep and circadian rhythms may be the key to un-
derstanding ketamine’s antidepressant effects and how past research has 
broadly neglected these foundational physiological factors, which has 
potentially contributed to the soaring number of translational failures. 
We also discuss that this lack of attention to sleep and circadian rhythms 
may have prevented our ability to understand and exploit the full po-
tential of ketamine and related rapid-acting interventions for the treat-
ment of depression and several other neuropsychiatric disorders. 
2. Sleep, depression, and rapid-acting antidepressants 
Sleep is a universal phenomenon observed in virtually all animals 
throughout the phylogenetic tree (Cirelli and Tononi, 2008). It occupies 
a significant proportion of our lifespan, and its sustained loss is highly 
detrimental. The disconnection from external environment that co-
incides with sleep entails vulnerability to predators and impedes other 
activities important for survival, such as foraging for food. It can be 
argued that for such a costly process to survive through evolution, it 
must offer some other significant functional benefit. While the precise 
function of sleep remains enigmatic, it is known to play an important 
role in the maintenance of neuronal homeostasis and in the regulation of 
synaptic plasticity (Kuhn et al., 2016), learning (Yang et al., 2014), and 
memory (Tononi and Cirelli, 2014). Sleep restores energy supplies, 
promotes recovery from cellular stress, repairs cellular and DNA dam-
age, clears metabolic byproducts, and regulates the immune system and 
temperature (Bass and Takahashi, 2010; Benington and Craig Heller, 
1995; Inokawa et al., 2020; Mackiewicz et al., 2007; Refinetti and 
Menaker, 1992; Reimund, 1994; Zada et al., 2019). Most importantly, 
sleep quality is directly reflected in cognitive function and psychological 
health (Bonnet, 1985; Ford and Kamerow, 1989; Wong et al., 2013). 
Depressive disorders are inherently associated with impaired sleep 
and circadian rhythm (Germain and Kupfer, 2008; Hasler et al., 2004; 
Norifumi et al., 2005; Nutt et al., 2008). Individuals with depression 
often exhibit decreased slow-wave sleep (SWS) (Ehlers et al., 1996) and 
lowered delta sleep ratio (Kupfer et al., 1990), which is the ratio of 
slow-wave activity (SWA; 0.5–4 Hz delta frequency) between the first 
two non-rapid-eye-movement (NREM) sleep episodes. Moreover, la-
tency of rapid-eye-movement (REM) sleep and increase in total time 
spent in REM sleep are typical polysomnographic findings in individuals 
suffering from depression (Nutt et al., 2008; Pillai et al., 2011). Notably, 
classic antidepressant drugs produce varying effects on sleep (Winokur 
et al., 2001), suppression of REM sleep in particular, although the exact 
role of sleep in governing their antidepressant effects remains obscure. 
Problems in sleep and circadian regulation (e.g. early morning awak-
enings, altered melatonin and cortisol secretion) (Germain and Kupfer, 
2008) often precede depressive episodes and may persist throughout 
remission, suggesting that their role in the pathogenesis of depres-
sion—at least in certain types—is primary rather than secondary (Li 
et al., 2013; McCarthy et al., 2019; Mishra et al., 2021). Indeed, 
emerging evidence has indicated that depressive symptoms can be 
alleviated by normalizing patients’ circadian misalignment and 
improving sleep quality (Ballesio et al., 2018; Cheng et al., 2019; 
Kalmbach et al., 2019; Manber et al., 2008; McCall et al., 2010). 
Paradoxically, sleep deprivation—which entails keeping patients 
awake for prolonged periods of time—is known to induce rapid but 
highly transient antidepressant effects in a subset of depressed patients 
(Wirz-Justice and Van den Hoofdakker, 1999). Its antidepressant effects 
are suggested to emerge through the modulation of homeostatic or 
circadian processes of sleep (Bunney and Bunney, 2013; Orozco-Solis 
et al., 2017; Vogel et al., 1980; Wirz-Justice and Van den Hoofdakker, 
1999; Wolf et al., 2016). Both sleep deprivation and ketamine regulate 
multiple molecular pathways involved in the neurobiology of sleep and 
share a similar circadian genomic signature in rodents (Duncan et al., 
2013b, 2017; Duncan et al., 2018; Kohtala et al., 2020; Morgan, 2017; 
Orozco-Solis et al., 2017). Ketamine affects circadian motor activity 
patterns, reduce nighttime wakefulness, and lessen sleep disturbances, 
all of which correlate with better therapeutic response (Duncan et al., 
2017, 2018; Vande Voort et al., 2017; Wang et al., 2021). Sleep depri-
vation leads to changes in well-known clock genes, which has been 
hypothesized to reset the dysfunctional clock gene machinery and sta-
bilize circadian rhythmicity in depressed patients (Bunney and Bunney, 
2013). 
One of the most striking features coupling rapid-acting antidepres-
sants to the neurobiology of sleep is the upregulation of SWA, which is 
thought to reflect the extent of synaptic potentiation preceding sleep 
(Rantamäki and Kohtala, 2020). Cortical excitation and synaptic 
potentiation are shared features of many interventions with rapid anti-
depressant potential, such as electroconvulsive therapy (ECT; Duman 
and Vaidya, 1998), transcranial magnetic stimulation (TMS; Baeken 
et al., 2013), and sleep deprivation (Vogel et al., 1980; Wehr et al., 1979; 
Wirz-Justice and Van den Hoofdakker, 1999). Several findings suggest 
that increased cortical activity—regardless of what triggers it—increase 
the buildup of homeostatic sleep pressure and lead to entrainment of 
circadian clockwork (Kohtala et al., 2020). Notably, postictal EEG 
slowing is one of the most frequently associated markers predicting 
positive therapeutic outcome of ECT (Farzan et al., 2014; Mayur, 2006; 
Nobler et al., 1993; Sackeim et al., 1996; Singh and Kar, 2017). 
Rodent studies were the first to demonstrate the connection between 
ketamine and the upregulation of SWA in the early 1990s (Feinberg and 
Campbell, 1995). This association was revisited in a recent clinical 
study, where ketamine-induced amplification of SWA during the first 
NREM sleep episode on the first night after treatment was associated 
with clinical improvement in depressed patients (Duncan et al., 2013b). 
Another study has suggested that baseline delta sleep ratio is a useful 
predictor for the antidepressant effects of ketamine (Duncan et al., 
2013a). These and other observations have led to hypotheses proposing 
that the interplay of increased synaptic strength and the neurobiological 
processes that occur during SWA is important for the emergence of rapid 
antidepressant effects as well as their sustainability (Duncan et al., 2019; 
Goldschmied and Gehrman, 2019; Rantamäki and Kohtala, 2020; Wolf 
et al., 2016). The clinical relevance of these ideas, however, remains to 
be thoroughly tested. Nevertheless, current evidence demonstrates that 
the time of day has an indisputable effect on neuronal function because 
cortical excitability increases with time spent awake (Huber et al., 2013) 
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and also undergoes circadian fluctuations (Kuhn et al., 2016; Ly et al., 
2016; Vyazovskiy et al., 2013). Therefore, considering that the key 
physiological effects invoked by rapid-acting treatments appear to 
converge on their capability to induce plasticity through transient 
cortical activation, it is also conceivable that the time of day influences 
their immediate and long-lasting actions in the brain. 
Moreover, when designing experiments, it may be crucial to take into 
account the time of day during treatment because subanesthetic-dose 
ketamine is known to have excitatory and arousal-promoting effects 
(Abdallah et al., 2018; Li et al., 2016; Lu et al., 2008; Zanos et al., 2018a, 
b). These properties have been documented to delay and/or disturb 
sleep when the drug is administered during the inactive period in both 
preclinical (Ahnaou et al., 2017) and clinical settings (Irwin et al., 
2013). It is tempting to speculate that some of the effects attributed to 
ketamine and other putative antidepressants in preclinical research may 
originate from unaccounted effects associated with the prolonged 
wakefulness of experimental animals resulting from the administration 
of stimulatory treatments in the early inactive period. This possibility 
further emphasizes the need to disclose the circadian time of treatment 
while reporting research in order to enable replication and proper 
comparison of results. 
Nevertheless, the impact of sleep or circadian biology on drug effects 
in general is only rarely considered (Ruben et al., 2019) even though 
preclinical guidelines (ARRIVE) enforced by numerous publishers have 
included them among the essential details in reporting research during 
the past decade (Kilkenny et al., 2010; Percie du Sert et al., 2020). 
However, it should be noted that the most widely used clinical guide-
lines (CONSORT, SPIRIT, and TIDieR) do not clearly state the necessity 
of disclosing time of day and focus instead on other time-associated 
variables, such as treatment duration and frequency (Chan et al., 
2013; Hoffmann et al., 2014; Schulz et al., 2010). These guidelines were 
initially issued to enhance the quality of research because it was found 
that important details that enable replication of clinical trials, including 
time-associated variables, were missing from half of the publications 
(Chan et al., 2013; Glasziou et al., 2008). 
3. Overview of sleep physiology in studies of rapid-acting 
antidepressants 
To the best of our knowledge, the impact of sleep or circadian time of 
drug administration has not been systematically evaluated in the context 
of treatment efficacy or potential translational bias in studies involving 
ketamine or other rapid-acting antidepressants. On the contrary, both 
sleep and chronobiology have received relatively little attention in the 
field. To illustrate this, we performed a literature search of English- 
language full-text original preclinical and clinical research articles 
about rapid-acting antidepressants published over the past decade 
(2009–2019) and archived in the Scopus database and examined the 
extent to which they considered sleep and circadian rhythm. 
Scopus database was chosen over another commonly used database, 
Web of Science, because of its equal and more extensive coverage, 
respectively, of basic medical science and clinical medicine (Li et al., 
2010a). The publication date range was selected because a steep in-
crease in ketamine-related research began around 2008 (Rantamäki, 
2019). The following query was used on August 7, 2020: ("rapid-acting 
antidepressant*" OR "rapid acting antidepressant*" OR "fast-acting an-
tidepressant*" OR "rapid antidepressant*" OR "electroconvulsive ther-
apy" OR "electroconvulsive shock" OR "ECS" OR "ECT" OR "ketamine") 
AND "antidepressant". The dataset was further restricted to preclinical 
(filtered by “animal” OR “animals”) and clinical studies (filtered by 
“human” OR “humans” OR “clinical”). Queries for preclinical and clin-
ical papers resulted in 1218 and 2383 results, respectively, of which 
1183 (97 %) and 2332 (98 %), respectively, were successfully sourced 
using open access and University of Helsinki library databases and 
analyzed using Alteryx Designer (Version 2020.3; Alteryx, Inc.; Irvine, 
CA, United States) and MATLAB (MATLAB 9.9; The MathWorks, Inc.; 
Natick, MA, United States) algorithm. Briefly, the script searched the 
availability of a paper from open access databases, and if failed, 
downloaded the article using Scopus API in accordance to its usage 
policy. The articles were downloaded as PDF files, optimized and con-
verted to text using open source libraries (Tesseract OCR Engine, Pop-
pler Tools), and imported to MATLAB array for a cleanup of non-text 
characters, hyphenated words, hyperlinks, and incorrect spellings. A 
count for the keyword “sleep” was subsequently performed using regular 
expression search, which was validated by a manual count of 50 
randomly selected studies. Details of the articles used in analysis are 
presented in Table S1. 
Metadata-level information (e.g., abstract or author-supplied and 
generated keywords) available from Scopus indicated that sleep-related 
discussion was essentially non-existent in the entire dataset. Thus, to 
better understand the extent to which sleep is discussed in the study of 
rapid-acting antidepressants overall, we conducted a regular expression 
count for the keyword “sleep” in full-text articles, including references. 
A significant majority of papers included in the dataset (80 % and 75 % 
of preclinical and clinical papers, respectively) did not include the word 
“sleep” (Fig. 1). A fraction of studies (17 % and 21 % of preclinical and 
clinical papers, respectively) mentioned the word “sleep” between one 
to five times, and considerably fewer (3% and 4% of preclinical and 
clinical papers, respectively) did so six or more times. Notably, this 
pattern persisted throughout the publication period included in our 
study and did not correlate with number of citations or publication 
impact factor (data not shown), suggesting that sleep remains a widely 
unacknowledged topic in the field, especially in preclinical research. 
Next, we performed a more detailed analysis of content, which was 
focused on the most cited research papers because they tend to receive 
the most attention within the scientific community, often guide future 
experiments, and act as the foundation for scientific theories. Thus, we 
selected the 100 most frequently cited original research articles 
involving a therapeutic intervention (i.e., reviews, case reports, and 
studies unrelated to antidepressant research were excluded) from both 
preclinical and clinical datasets for further manual analysis (Fig. 1). 
Notably, the vast majority of the publication forums belonged to high- 
ranked journals. The binary inclusion of the keyword “sleep” was 
searched from the main text, excluding references. Of these most 
frequently cited preclinical and clinical papers, only 11 % and 29 %, 
respectively, mentioned the word “sleep” more than once (Fig. 2), 
mirroring the results of the automated search. Furthermore, the few 
articles that did mention “sleep” typically did not discuss the role of 
sleep in the observed effects but rather mentioned it in the context of 
treatment timing (e.g., stating that the drug was administered “after 
overnight sleep at the clinic”) or in the introduction mentioning sleep 
impairments as one of the frequently observed symptoms in depressed 
patients. 
Next, we investigated whether the observed lack of consideration for 
sleep was reflected in research practices of the 100 most frequently cited 
preclinical studies by analyzing them for the inclusion of details related 
to housing light cycles and the phases during which treatments were 
administered and behavioral testing was conducted. As expected, ro-
dents (rats and/or mice) were the most widely used animal species in 
these studies, whereas two of the studies had been done in zebrafish. 
Notably, only eight papers reported administering the treatments during 
the animals’ active period (Fig. 2). Of these eight, two were conducted 
with day-active zebrafish (Riehl et al., 2011; Zakhary et al., 2011). 
Twenty of the animal studies were conducted during the inactive period, 
and most of the studies (72 %) did not clearly disclose the circadian time 
of treatment. It can be speculated, however, that a significant pro-
portion—if not all—of the studies that omitted this information were 
conducted during the inactive period, as is customary in rodent research 
(Hawkins and Golledge, 2018). 
Ninety-one of the preclinical studies employed behavioral analyses. 
Similar to circadian time of treatment, circadian time of behavioral 
testing was disclosed in only 35 studies, of which only seven had been 
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conducted during the animals’ active period, whereas 20 had been 
conducted during the inactive period. Eight studies were counted as 
“mixed” because they either involved behavioral testing in both circa-
dian phases or because the experiment times were only partially 
disclosed. 
With regard to clinical practice and research, no existing treatment 
guidelines specify the optimal time for ketamine administration for the 
treatment of depression. Routine practice in the clinic is, somewhat 
obviously, to administer treatments during “office hours” that are 
roughly aligned with the early wake of the average human circadian 
cycle. Especially if fasting before treatment is required, treatments are 
typically administered as early in the morning as possible to reduce 
patient discomfort. While having an empty stomach is a stricter pre-
requisite for ECT, the medical agencies in both the United States and 
European Union also recommend fasting before administration of S- 
ketamine to avoid nausea, which is commonly experienced after treat-
ment (European Medicines Agency, 2020; Daly et al., 2018; Janssen 
Pharmaceutical Companies, 2020; Popova et al., 2019). These practices 
were evident in our analysis of the 100 most frequently cited clinical 
articles; the disclosed treatment times were most often in the morning 
(19 studies), in the afternoon (one study; Baeken et al., 2013), or both in 
the morning and in the afternoon (one study; Ferrucci et al., 2009) 
(Fig. 2). Only one study stood out from the rest as it administered 
ketamine late in the evening (Irwin et al., 2013). In the experiment, 
terminally ill patients with comorbid depression received a nightly 
subanesthetic oral dose of ketamine that—perhaps unexpectedly—led to 
difficulty falling asleep as one of the reported adverse effects. One study 
involved overnight sleep deprivation as the treatment (Gorgulu and 
Caliyurt, 2009) and is therefore not directly comparable to the other 
protocols in terms of timing disclosure of circadian time of treatment. It 
should be noted, however, that only 23 out of the 100 clinical studies 
disclosed circadian time of treatment, mirroring the findings related to 
the preclinical literature. Regarding disclosure of circadian time of 
treatment, it should be noted that most of the timing-related information 
in clinical studies was phrased in a vague manner that left room for 
subjective interpretation (i.e., “before lunch” or “after overnight fast”). 
Additionally, it was apparent that the clinical studies were conducted 
during a significantly more homogeneous time range than the preclini-
cal studies. Most experiments were aligned with early subjective wake of 
the subjects, and even the most ambiguous phrasing (e.g., “morning”) 
would generally be interpreted to span 5–6 h. In contrast, the circadian 
time of treatment in preclinical studies was distributed across both 
subjective preferred sleep and wake, and commonly reported ranges 
were as wide as 12 h (i.e., equal to the phase of a 12:12 h light cycle). 
Taken together, the results of this perspective demonstrate an 
evident lack of consideration for sleep in experiment planning and 
Fig. 1. Mention of the keyword “sleep” in studies on rapid-acting antidepressants published between 2009 and 2019. A) A temporal overview of the whole 
dataset demonstrating counts for the keyword “sleep” in preclinical (n = 1183; left) and clinical (n = 2332; right) research papers. B) Citation count distribution in 
the dataset approximately follows the inverse-square power law—only a small fraction of all articles receives significant attention in the field. 
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reporting in studies investigating the effects of rapid-acting antide-
pressants. Admittedly, the employed method of analyzing the whole 
dataset using regular expression search was limited in nature—the 
search was limited to the keyword “sleep” without considering the use of 
its synonyms and inflections and included the use of the word in refer-
ence lists, and it may have missed some uses owing to optical character 
recognition. Nevertheless, the results indicate that sleep is overall a very 
marginal topic in the field of antidepressant research. Furthermore, the 
manual search of the most cited articles found that a similar proportion 
of papers mentioned the keyword, supporting the validity of the method. 
The fact that only a fifth of the studies in our dataset mentioned the word 
“sleep” demonstrates the existence of an implicit assumption that sleep 
and time of day are irrelevant to the outcomes of these experiments. This 
finding was further reinforced by our manual analysis of the top-cited 
preclinical and clinical studies, of which fewer than 30 % disclosed 
the experiment times. This oversight is surprising considering that many 
publishers have vowed to enforce reporting guidelines stating the ne-
cessity of disclosing experiment times. Our results demonstrate that 
these guidelines are not followed in practice, preventing the proper 
replication of studies and comparison of their results. The results also 
illustrate a substantial divergence between preclinical and clinical 
administration practices: while patients typically receive treatments 
during their early wake, experimental animals are commonly dosed 
during their resting phase. 
4. Conclusion 
The concepts highlighted by this perspective accentuate the 
complexity of current research on rapid-acting antidepressants. In the 
past decade, the 200 most frequently cited clinical and preclinical 
research reports—likely representing the most influential experiments 
in the field of antidepressant research—commonly ignored sleep and 
circadian physiology in experiment planning and reporting. 
One issue of particular concern is that the preclinical research studies 
that did disclose sleep-related variables and/or timing of experiment 
typically administered ketamine and other excitatory treatments during 
animals’ resting phase, potentially causing sleep disruption. This not 
only contradicts the regular sleep physiology of the animals but is also 
the polar opposite of clinical practice, in which patients are treated 
during their early waking hours (Fig. 3). Introducing such stimulatory 
treatments at night is likely to disrupt physiological sleep, which may 
influence or even account for experimental results. Indeed, it has been 
repeatedly shown that circadian disruption and incorrect circadian time 
of experiment induce significant variation in behavioral testing results 
(Cain et al., 2004; Chaudhury and Colwell, 2002; Karatsoreos et al., 
2011; Verma et al., 2010) and in the effects of various pharmacological 
agents (Dallmann et al., 2014). This not only creates a clear divergence 
between preclinical research and standard clinical practice but also 
predisposes study results to a variety of unknown physiological and 
neurobiological sleep-related effects, such as increased synaptic poten-
tiation due to a form of sleep deprivation. 
Because this critical consideration has largely been omitted from the 
research literature—possibly owing to a lack of understanding of the 
important role sleep plays in physiological processes—it is conceivable 
that the sharp contrast in the features of preclinical and clinical research 
practices may have contributed to the soaring number of failed clinical 
trials of rapid-acting antidepressants. Another possible reason for the 
improper circadian time of experimentation appears to be simply that it 
is more convenient to conduct the experiments in well-lit environment. 
Indeed, while limited in number, both studies involving day-active 
Fig. 2. A) Proportion of the 100 most frequently cited preclinical and clinical research articles mentioning the word “sleep”. B) Disclosure of information regarding 
circadian time of treatment in the 100 most frequently cited preclinical (left) and clinical (right) research articles. C) The treatments used in the 100 most frequently 
cited preclinical and clinical studies. Abbreviations: ECS, electroconvulsive shock; TMS, transcranial magnetic stimulation; ECT, electroconvulsive therapy; DBS, deep 
brain stimulation. 
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zebrafish were conducted during the active period of the animals (Riehl 
et al., 2011; Zakhary et al., 2011), whereas experiments on nocturnal 
laboratory rodents were predominantly conducted during their inactive 
period. Even though the consequences of different circadian times of 
treatment on the effects of rapid-acting antidepressants require further 
research, we would argue that convenience is not an acceptable reason 
to introduce a significant source of variation to the results without at 
least properly addressing the practice while reporting research. In light 
of more recent hypotheses regarding antidepressant actions (Duncan 
et al., 2019; Morgan, 2017; Rantamäki and Kohtala, 2020; Zanos et al., 
2018b), administering treatments during a more species-appropriate 
time would be an easy way to untangle the contribution of circadian 
disruption from the observed behavioral effects. We hope that the data 
presented in this report will encourage investigators to consider the 
effects of sleep (or lack thereof) in their experiments and clinical prac-
tice, and support research reproducibility by—at the very least—clearly 
disclosing circadian times for all experiments. 
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